[1]陆晔,邵红,程旭,等.低分子肝素对慢性病贫血患者Hb和C反应蛋白水平影响的初步研究[J].现代检验医学杂志,2019,34(01):130-132.[doi:10.3969/j.issn.1671-7414.2019.01.034]
LU Ye,SHAO Hong,CHENG Xu,et al.Preliminary Study on the Effects of Low Molecular Weight Heparinon Hb and C Reactive Protein Levels in Patients with Chronic Anemia[J].Journal of Modern Laboratory Medicine,2019,34(01):130-132.[doi:10.3969/j.issn.1671-7414.2019.01.034]
点击复制
低分子肝素对慢性病贫血患者Hb和C反应蛋白水平影响的初步研究(
)
《现代检验医学杂志》[ISSN:/CN:]
- 卷:
-
第34卷
- 期数:
-
2019年01期
- 页码:
-
130-132
- 栏目:
-
检验与临床
- 出版日期:
-
2019-02-28
文章信息/Info
- Title:
-
Preliminary Study on the Effects of Low Molecular Weight Heparin
on Hb and C Reactive Protein Levels in Patients with Chronic Anemia
- 文章编号:
-
1671-7
414(2019)01-130-03
- 作者:
-
陆晔; 邵红; 程旭; 潘湘涛
-
(苏州大学附属太
仓医院肿瘤科，江苏太仓215400)
- Author(s):
-
LU Ye; SHAO Hong; CHENG Xu; PAN Xiang-tao
-
(D
epartment of Oncology，
the Taicang Hospital Affiliated to Suzhou University；Jiangsu Taicang 2154
00，China)
-
- 关键词:
-
低分子肝素(LMWH); 慢性病贫血(ACD); C反应蛋白(CRP); 血
红蛋白(Hb); 治疗; 机制
- 分类号:
-
R556.9；R446.11
- DOI:
-
10.3969/j.issn.1671-7414.2019.01.034
- 文献标志码:
-
A
- 摘要:
-
目的初步研究低分子肝素(LMWH)在治疗慢性病贫血(ACD)
患者中的临床意义。方法对90例伴有血栓形成或血浆D-二聚体很
高而有血栓形成倾向的ACD患者应用LMWH(4 000 U/天，7～15天)治疗，并测定治疗前后Hb和
C-反应蛋白(CRP)水平以观察它们的变化情况，同时分析其临床意义。结果〖
①贫血组治疗前Hb水平为93.51±15.55 g/L，明显低于治疗后的100.95±12.
97g/L，差异有统计学意义( t=2.527 8，P <0.05)。②无贫血组治疗前Hb水平为133.
09±10.69 g/L，与治疗后的135.57±13.09 g/L比较差异无统计学意义( t=0.7417，P
>0.05)。③治疗前贫血组CRP为49.31±39.07 mg/L，明显高于治疗后的29.73±39.0
7 mg/L，差异有统计学意义( t=2.483 4，P <0.05)。④无贫血组治疗前CRP水平为18
.08±16.77 mg/L，与治疗后的18.24±12.31 mg/L比较差异无统计学意义( t=0.023
7，P >0.05)。⑤治疗前后CRP水平与Hb水平均呈负相关(分别为 r=－0.425 9，P <0
.01和 r=－0.234 7，P <0.05)。结论LMWH上调ACD患者的Hb
水平，可以改善患者的贫血，可能机制是下调CRP水平。
- Abstract:
-
Objective To preliminary study the significance
of low molecular weight heparin (LMWH) in the treatment the patients of anemia
of chronic diseases(ACD)．Methods Used LMWH(4 000 U/day，
7～15 days) to therapy the patients with thrombus formation or plasma D-two dim
er(D-D) which was high and had a tendency to thrombosis，to observe change of t
he levels of CRP and Hb in patients in pretherapy and post-therapy，and to ana
lysis of its clinical significance．Results ①In anemia g
roup the Hb levels in pretherapy were 93.51±15.55 g/L，which were lower th
an 100.95±12.97 g/L in post-therapy( t=2.527 8，P <0.05)．②In non-an
emia group，the level of Hb were not difference between the pretherapy and post
-therapy (rspectively were 133.09±10.69 g/L and 135.57±13.09 g/L， t=0
.741 7，P >0.05)．③In anemia group，the levels of CRP were 49.31±39.07 m
g/L in pretherapy，which were higher than 29.73±39.07 mg/L in post-therapy
( t=2.483 4，P <0.05)．④In non-anemia group，the level of CRP were not di
ffernce between the pretherapy and post-therapy (respectively were 18.08±16.
77 mg/L and 18.24±12.31 mg/L， t=0.023 7，P >0.05)．⑤There were all neg
tive correlation between the CRP and Hb in pretherapy and post-therapy(respecti
vely were r =-0.425 9， P <0.01 and r =-0.234 7， P <0.05)．
Conclusion LMWH could up-regulate the levels of Hb，and bette
r
for the degree of anemia in patients with ACD．The possible mechanism is to down
regulate the level of CRP．
参考文献/References:
[1］潘湘涛，陆晔，程旭，等．癌性患者血清hepcidin及炎症介质细胞因
子表达特点及其与贫血的关系［J］．现代检验医学杂志，2011，26(4)：22-24，27．
PAN Xiangtao，LU Ye，CHENG XU，et al．Expression characters of serum
hepcidin，inflammatory mediators and cytokines in patients with cancer and the
relation
s between anemia and them［J］．J Mod Lab Med，2011，26(4)：22-24，27．
[2］ZHANG A S，YANG F，WANG J H，et al．Hemojuvelin-neogenin interaction is
re
quired for bone morphogenic protein-4-induced hepcidin expression［J］．J Biol
Chem，2009，284(34)：22580-22589．
[3］NEMETH E，TUTTLE M S，POWELSON J，et al．Hepcidin regulates cellular iron
efflux by binding to ferroportin and inducing its internalization［J］．Science
，2004，306(5704)：2090-2093．
[4］程旭，潘湘涛，张媛，等．C反应蛋白及血清铁调素在肿瘤患者中的表达及其与
贫血的关系［J］．中国继续医学教育，2017，9(7)44-45．
CHEN Xu，PAN Xiangtao，ZHANG Yuan，et al．The expression of C-react
ive protein and serum hepcidin in tumor patients and its relationship with anemi
a［J］．Ch
ina Continuing Medical Education，2017，9(7)44-45．
[5］POLI M，ASPERTI M，RUZZENENTI P，et al．Hepcidin antagonists for potentia
l treatments of disorders with hepcidin excess［J］．Front Pharmacolgy，2014，5
：86．
[6］POLI M，GIRELLI D，CAMPOSTRINI N，et al．Heparin：A potent inhibitor of h
epcidin expression in vitro and in vivo［J］．Blood，2011，117(3)：997-1004．
ZK
Ann Clin Biochem，2017，54(4)：448-462．
[11］FRECKMANN G，SCHMID C，BAUMSTARK A，et al．System accuracy evaluation of
43 blood glucose monitoring systems for self-mornitoring of blood glucose acco
rding to DIN EN ISO15197［J］．J Diabetes Sci Technol，2012，6(5)：1060-1075．
[12］HALLDORSDOTTIR S，WARCHAL-WINDHAM M E，WALLACE JF，et al．Accuracy eval
uation of five blood glucose monitoring systems：the North American comparator t
r
ial［J］．J Diabetes Sci Technol， 2013，7(5)：1294-1304．
[13］FOBKER M．Stability of glucose in plasma with different anticoagul
ants［J］．Clin Chem Lab Med，2014，52(7)：1057-1060．
[14］屈引婷．重选血葡萄糖测定抗凝剂实验评价［J］．现代检验医学杂志，2005，20(
5)：83-84．
QU Yinting．Experiment evaluation for re-election anticoagulant of bloo
d glucose measurement［J］．Journal of Modern Laboratory Medicine，2005，20(5)：
83-84．
[15］DIETZEN D J，WILHITE T R，RASMUSSEN M，et al．Point-of-care glucose an
alysis in neonates using modified quinoprotein glucose dehydrogenase［J］．Diabe
te
s Technol Ther，2013，15(11)：923-928．
[16］叶桂样，黄瑞勋，卓雪芽，等．不同品牌血糖仪在检测氟化钠抗凝血血糖中的偏倚
研究［J］．国际检验医学杂志，2014，34(13)：1737-1738．
YE Guiyang，HUANG Ruixun，ZHUO Xueya，et al．Bias study of blood sugar for
different brand glucose meter for sodium fluoride anticoagulant［J］．Internati
onal Journal of Laboratory Medicine，2014，34(13)：1737-1738．
[17］廖远泉，廖安琪．POCT-便携式血糖仪及其准确性影响因素研究概述［J］．临床
检验杂志(电子版)，2015，4(2)：876-881．
LIAO Yuanquan，LIAO Anqi．Research progress P OCT-portable blood glucose
meter and accuracy influencing factors［J］．Chinese Journal Clinical Laboratory
Science (Electronic Edition)，2015，4(2)：876-881．
备注/Memo
- 备注/Memo:
-
作者简介：陆晔(1970-)，女，硕士，主任医师，主要从事肿瘤的基础与
临床研究。
通讯作者：潘湘涛(1963-)，男，博士，教授，主要从事肿瘤的基
础与临床研究，Email：panxiangtao@csco.ac.cn。
更新日期/Last Update:
2019-02-28